T. Rowe Price Health Sciences Fund (PRHSX)

Fund Assets	11.85B
Expense Ratio	0.83%
Min. Investment	$500,000
Turnover	61.60%
Dividend (ttm)	10.10
Dividend Yield	10.35%
Dividend Growth	-1.44%
Payout Frequency	Annual
Ex-Dividend Date	Dec 15, 2025

Previous Close	98.52
YTD Return	17.93%
1-Year Return	41.02%
5-Year Return	25.16%
52-Week Low	75.20
52-Week High	98.96
Beta (5Y)	0.66
Holdings	149
Inception Date	Dec 29, 1995

About PRHSX

T. Rowe Price Health Sciences Fund is an actively managed mutual fund focused on the health sciences sector. Its primary objective is to achieve long-term capital appreciation by investing at least 80% of its net assets in the common stocks of companies involved in health care, medicine, or life sciences. The fund’s investment universe spans pharmaceuticals, biotechnology, medical device manufacturers, and health care service providers, targeting both large- and mid-capitalization firms. The fund’s holdings are diversified across key players in the health care industry, with significant allocations to leading names such as Eli Lilly and UnitedHealth Group. This approach allows the fund to capture growth opportunities driven by medical innovation, demographic trends, and advances in health technologies. It typically maintains a concentrated portfolio, with the top ten holdings representing a substantial portion of total assets, emphasizing the manager’s high-conviction ideas. With an inception dating back to 1995, the fund has established itself as a notable vehicle for investors seeking specialized exposure to the health care sector. It plays a significant role in the market by offering focused access to a defensive and innovative segment of the global economy, making it a reference point among sector-specific mutual funds.

• Fund Family: T. Rowe Price
• Category: Health
• Performance Rating: Above Average
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: PRHSX
• Index: S&P 500 TR

Performance

PRHSX had a total return of 41.02% in the past year, including dividends. Since the fund's inception, the average annual return has been 13.40%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
THISX	T. Rowe Price Health Sciences Fund-i Class	0.68%

Top 10 Holdings

53.33% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	14.27%
Aggregate Miscellaneous Equity	n/a	7.63%
Johnson & Johnson	JNJ	6.62%
UnitedHealth Group Incorporated	UNH	5.99%
AbbVie Inc.	ABBV	5.10%
Merck & Co., Inc.	MRK	4.00%
Gilead Sciences, Inc.	GILD	2.82%
Thermo Fisher Scientific Inc.	TMO	2.52%
Vertex Pharmaceuticals Incorporated	VRTX	2.28%
Bristol-Myers Squibb Company	BMY	2.11%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 15, 2025	$10.1023	Dec 16, 2025
Dec 16, 2024	$10.2497	Dec 17, 2024
Dec 15, 2023	$4.578	Dec 18, 2023
Dec 15, 2022	$1.5867	Dec 16, 2022
Dec 15, 2020	$0.930	Dec 16, 2020
Dec 16, 2019	$5.030	Dec 17, 2019

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Aug 27, 2026

Data Sources Report a data error